About 37,070 results

Efficacy of a Fourth Dose of Covid-19 mRNA Vaccine against Omicron
The New England Journal of Medicine; Mandelboim M, .

Mar 16th, 2022 - In this open-label, nonrandomized clinical study, we assessed the immunogenicity and safety of a fourth dose of either BNT162b2 (Pfizer–BioNTech) or mRNA-1273 (Moderna) administered 4 months after the third dose in a series of three BNT162b2 doses (ClinicalTrials.gov numbers, NCT05231005. opens in new tab and NCT05230953. opens in new tab; the protocol is available w...

Antibody Response to a Fourth Messenger RNA COVID-19...
Annals of Internal Medicine; Caillard S, Thaunat O et. al.

Jan 11th, 2022 - Antibody Response to a Fourth Messenger RNA COVID-19 Vaccine Dose in Kidney Transplant Recipients: A Case Series.|2022|Caillard S,Thaunat O,Benotmane I,Masset C,Blancho G,|prevention & control,genetics,

Herpes Zoster Following a Nucleoside-Modified Messenger RNA COVID-...
Cutis Dezoteux F, Massip É et. al.

Feb 19th, 2022 - Herpes zoster (HZ) was suspected as a predictive cutaneous manifestation of COVID-19, with a debated prognostic significance. We report a series of 5 cases of HZ occurring after vaccination with a nucleoside-modified messenger RNA (mRNA) COVID-19 vaccine (Comirnaty, Pfizer-BioNTech). These new cases do not prove causality between COVID...

Fourth dose of COVID vaccine offers only slight boost against Omicron infection
Nature Mallapaty S.

Feb 23rd, 2022 - A fourth dose of a COVID-19 vaccine restores antibodies to levels observed after the third dose but provides only a modest boost in protection against infection, according to a small trial carried out in Israel1.

Fourth dose of COVID vaccine offers only slight boost again...
Nature Mallapaty S

Feb 25th, 2022 - Fourth dose of COVID vaccine offers only slight boost against Omicron infection.|2022|Mallapaty S,|

Myocarditis after BNT162b2 mRNA Vaccine against Covid-19 in...
The New England Journal of Medicine; Mevorach D, Anis E et. al.

Oct 7th, 2021 - Approximately 5.1 million Israelis had been fully immunized against coronavirus disease 2019 (Covid-19) after receiving two doses of the BNT162b2 messenger RNA vaccine (Pfizer-BioNTech) by May 31, 2021. After early reports of myocarditis during adverse events monitoring, the Israeli Ministry of Health initiated active surveillance. We retrospectively re...

Fourth dose of COVID-19 vaccines in Israel.
The Lancet. Respiratory Medicine; Burki TK

Jan 15th, 2022 - Fourth dose of COVID-19 vaccines in Israel.|2022|Burki TK,|

Myocarditis Following mRNA COVID-19 Vaccine.
Pediatric Emergency Care; Visclosky T, Theyyunni N et. al.

Nov 4th, 2021 - A growing number of adolescents are being diagnosed with acute myocarditis following mRNA COVID-19 vaccinations. This case describes an adolescent who presented to the emergency department with chest pain and tachycardia following the Pfizer-BioNTech COVID-19 vaccination. Point-of-care ultrasound was performed prior to the return of laboratory studies and reve...

Fourth COVID-19 Vaccine Dose Increases Low Antibodies.
JAMA Abbasi J

Feb 9th, 2022 - Fourth COVID-19 Vaccine Dose Increases Low Antibodies.|2022|Abbasi J,|blood,immunology,blood,immunology,

Fourth COVID-19 Vaccine Dose Boosts Antibodies Fivefold in Israeli Study, PM Says

Jan 5th, 2022 - JERUSALEM (Reuters) - A fourth dose of COVID-19 vaccine boosts antibodies five-fold a week after the shot is administered, Israeli Prime Minister Naftali Bennett said on Tuesday, citing preliminary findings of an Israeli study. "A week into the fourth dose, we know to a higher degree of certainty that the fourth dose is safe," Benne...

Fourth Dose of BNT162b2 mRNA Covid-19 Vaccine...
The New England Journal of Medicine; Magen O, Waxman JG et. al.

Apr 14th, 2022 - With large waves of infection driven by the B.1.1.529 (omicron) variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), alongside evidence of waning immunity after the booster dose of coronavirus disease 2019 (Covid-19) vaccine, several countries have begun giving at-risk persons a fourth vaccine dose. To evaluate t...

Effectiveness of a Fourth Dose of COVID-19 mRNA V...
Annals of Internal Medicine; Tan CY, Chiew CJ et. al.

Sep 13th, 2022 - Effectiveness of a Fourth Dose of COVID-19 mRNA Vaccine Against Omicron Variant Among Elderly People in Singapore.|2022|Tan CY,Chiew CJ,Lee VJ,Ong B,Lye DC,|epidemiology,prevention & control,genetics,

Effectiveness of fourth dose of COVID-19 vaccine aga...
International Journal of Epidemiology; Zeng J, Szanyi J et. al.

Dec 17th, 2022 - Effectiveness of fourth dose of COVID-19 vaccine against the Omicron variant compared with no vaccination.|2022|Zeng J,Szanyi J,Blakely T,|

Psoriasiform Dermatitis Associated With the Moderna COVID-19 Messenger RNA Vaccine
Yahya Daneshbod, MD, Iqbal Ahmed, MBBS et. al.

Nov 16th, 2022 - To the Editor: The Moderna COVID-19 messenger RNA (mRNA) vaccine was authorized for use on December 18, 2020, with the second dose beginning on January 15, 2021. 1-3 Some individuals who received the Moderna vaccine experienced an intense rash known as “COVID arm,” a harmless but bothersome adverse effect that typically appears withi.

Preserved recognition of Omicron spike following COVID-19 messe...
American Journal of Obstetrics and Gynecology; Bartsch YC, Atyeo C et. al.

Apr 18th, 2022 - SARS-CoV-2 infection is associated with enhanced disease severity in pregnant women. Despite the potential of COVID-19 vaccines to reduce severe disease, vaccine uptake remained relatively low among pregnant women. Just as coordinated messaging from the Centers for Disease Control and Prevention and leading obstetrics organizations began to increase vaccine co...

Effectiveness of a fourth dose of covid-19 mRNA v...
BMJ (Clinical Research Ed.); Grewal R, Kitchen SA et. al.

Jul 7th, 2022 - To estimate the marginal effectiveness of a fourth versus third dose and the vaccine effectiveness of mRNA covid-19 vaccines BNT162b2 and mRNA-1273 against any infection, symptomatic infection, and severe outcomes (hospital admission or death) related to the omicron variant. Test negative design. Long term care facilities in Ontario...

A Bivalent Omicron-Containing Booster Vaccine against Covid-19...
The New England Journal of Medicine; Chalkias S, Harper C et. al.

Sep 17th, 2022 - The safety and immunogenicity of the bivalent omicron-containing mRNA-1273.214 booster vaccine are not known. In this ongoing, phase 2-3 study, we compared the 50-μg bivalent vaccine mRNA-1273.214 (25 μg each of ancestral Wuhan-Hu-1 and omicron B.1.1.529 [BA.1] spike messenger RNAs) with the previously authorized 50-μg mRNA-1273 booster. We administered mRNA-1273.214 or mRNA-1273 as a second bo...

Hospitalized patients with severe COVID-19 during the Omicron wave...
Clinical Infectious Diseases : an Official Publication Of... Brosh-Nissimov T, Hussein K et. al.

Jun 21st, 2022 - Waning vaccine-immunity and an increased incidence of COVID-19 during the Omicron outbreak led the Israeli Ministry of Health to recommend a fourth dose of BNT162b2 for high-risk individuals. This study assessed the effect of that dose for hospitalized patients with severe/critical, breakthrough COVID-19. In this multi-center retros...

Nucleoside-modified messenger RNA COVID-19 vaccine p...
Journal of Medical Virology; Roncati L, Corsi L

Mar 7th, 2021 - On March 11, 2020, the World Health Organization declared coronavirus disease 2019 (COVID-19) a pandemic; from that date, the vaccine race has begun, and many technology platforms to develop a specific and effective COVID-19 vaccine have been launched in several clinical trials (protein subunit, RNA-based, DNA-based, replicating viral vect...

Cellular and humoral response to the fourth BNT162b2 mRNA COVID-
European Journal of Haematology; Benjamini O, Gershon R et. al.

Oct 9th, 2022 - We assessed the humoral and cellular response to the fourth BNT162b2 mRNA COVID-19 vaccine dose in patients with CLL. A total of 67 patients with CLL and 85 age matched controls tested for serologic response and pseudo-neutralization assay. We also tested the functional T-cell response by interferon gamma (IFNγ) to spike protein in 26 patients. Two week...